RTRX – Retrophin- From Hedgefund to Biotech

Introduction Started in 2010 as an “extracurricular activity” by hedge fund manager Martin Shkreli, Retrophin was officially formed in February 2011 to focus on developing drugs for orphan indications. The.

CLSN – Cautious on Celsion

With Jason Chew and Juan Pedro Rodríguez Serrate We are coming close to the top-line data release of Celsion’s Phase 3 trial of Thermodox in primary liver cancer. We have.

ONTY – Preparing For The Next Move

Oncothyreon Inc (ONTY)-Nasdaq Oncothyreon’s getting a lot of attention ahead of its near term catalyst set for Q1 2013 with the final analysis of its pivotal START trial. Results expected.

3 Phase III trials set to read out in 2013 – ONTY, CLSN, NLNK

With Patrick Crutcher Some of the biotech sector’s most highly anticipated catalysts approach in early 2013. Nearly every issues has been debated upon between the first two companies, while the.

What to expect at SABCS12 from Celldex

As Celldex Therapeutics comes closer to their presentation at the San Antonio Breast Conference Symposium this weekend, we wanted to provide a primer on their CDX-011 program. With around $370.

2012 ASH Meeting – Myelofibrosis, Lymphoma, Myeloma

It’s going to be a busy few days at ASH, which begins December 8 in Atlanta. A huge amount of data will be presented; here is an overview of some.

FOLD – Getting Ready For The New Uptrend

Amicus Therapeutics, Inc. (NASDAQ: FOLD) With FOLD on the move again, we wanted to look at how the stock is performing from a technical perspective , especially after Patrick’s report.

Rheumatoid Arthritis Treatments: The Decade Ahead

Rheumatoid arthritis sufferers have seen dramatic improvements in the standard of care over the last 25 years. Prior to the approval of methotrexate (MTX) in 1988, the best that doctors.

FOLD – Bullish on Amicus Therapeutics

With Phase 3 data expected from Amicus Therapeutics (NASDAQ : FOLD), we wanted to take the time to do a thorough analysis of the trial and what to expect. Jason.

INCY, LLY – Baricitinib at ACR 2012

Incyte Corp and Eli Lilly participated in an investor meeting following the presentation of Phase II data for their jointly developed JAK inhibitor, baricitinib, at the American College of Rheumatology.

FOLD – Phase II Amigal Co-administration Update

Amicus Therapeutics released updated data Thursday for its chaperone molecule Amigal (migalastat) for Fabry disease at the American Society of Human Genetics (ASHG) Annual Meeting. Results looked good, continuing to.

DCTH – Commercial prospects and valuation

In our previous note, we discussed why we thought that a drug with orphan status, fast-track that tackles metastatic disease would receive a 6-month priority review. However, the FDA didn’t.

IBB – Nasdaq Biotechnology Index – Reaching a Critical Point

iShares Nasdaq Biotechnology (IBB)-NasdaqGM Typically, the best indicator of the action in our biotech portfolio is the $IBB. By looking at it we get the whole picture of the pressure.

PBYI – Quick look at Puma Biotechnology

We wanted to take a moment to take a quick look at Puma Biotechnology (NYSE: PBYI). They recently raised $130M in cash from a public offering. The company has some.

Upcoming medical conferences – Q4 2012

With the beginning of November, we enter the home stretch for some of the major medical meetings that will serve as pivotal events for some companies. We have attempted to.

What we’re looking for at ASH 2012

On Monday, November 5th, abstracts submitted to 2012 Annual Meeting of the American Society of Hematology (ASH) Annual Meeting will be published online. A time has not been released, but.

CPRX – Catalyst Pharmaceutical Partners – Promising But Still Early

Catalyst Pharmaceutical Partners Inc. (CPRX) -NasdaqCM Catalyst: Phase IIb trial results Sentiment : Bullish Tiny Catalyst Pharmaceutical Partners is expected to disclose top-line results from its pivotal Phase IIb study.

ZIOP – Ziopharm is undervalued

We have previously posted a long look at Ziopharm Oncology here. We feel the story is worth reiterating given near-term events and our view that the company is undervalued. Recent.

Biotech and Pharma earnings preview

Starting after-hours on Tuesday, we’ll see a lot of biotech and pharmaceuticals earnings, guidance, and outlook on their current programs. With the market cooling off, companies will be under pressure.

ISIS and AEGR – Where do they stand after the FDA Advisory Committee meetings?

October 17 and 18, 2012 saw back-to-back meetings of the FDA Endocrine and Metabolic Drugs Advisory Committee (EMDAC) to review pending new drug applications (NDAs) for two drugs for homozygous.

Browsing 20 / 457 articles